Triple antiviral therapy shows promise in mild-to-moderate COVID-19 in HK study
27 May 2020
byChristina Lau
A triple antiviral regimen of interferon (IFN) beta-1b, lopinavir-ritonavir and ribavirin, given within 7 days of symptom onset, is superior to lopinavir-ritonavir alone in alleviating symptoms and shortening the duration of viral shedding and hospital stay in patients with mild-to-moderate coronavirus disease 2019 (COVID-19), a prospective open-label phase II study in Hong Kong has shown.
